Aortech International PLC
1 October 2001
AORTECH INTERNATIONAL PLC
New Trileaflet Heart Valve
Commencement of Regulatory Trials
AorTech International plc, the Scottish-based manufacturer of cardio-vascular
devices, announces the commencement of the regulatory testing phase of its new
synthetic trileaflet heart valve prior to the commencement of clinical trials
in patients in the latter part of 2002.
The new trileaflet heart valve, made from Elast-EonTM a novel synthetic
material, aims to surmount the current clinical problems of mechanical valves
and bioprosthetic (tissue) valves which, in the case of mechanical valves,
require daily anticoagulant treatment for patients and, in the case of
bioprosthetic valves, have a limited lifespan.
The development and testing work to date has demonstrated excellent results in
terms of the valve's performance. The formal regulatory testing will be
carried out in the European Union and in the United States to comply with the
requirements of both the European Regulatory Bodies and the FDA in the USA.
Eddie McDaid, Chief Executive of AorTech, commented:
'The excellent results of our development work to date on both the material
and the design of the valve has enabled us to reach the stage of regulatory
testing which is required prior to starting clinical trials in patients in the
latter part of next year.
'This development is indeed a milestone for AorTech and the heart valve
industry in that the new synthetic trileaflet heart valve will represent the
major innovation in replacement of diseased and damaged heart valves over the
last 25 years. This milestone could not have been reached without the
substantial work and efforts of our development teams, both in the United
Kingdom and in Australia and I take this opportunity of acknowledging their
outstanding contribution in bringing the development of this new heart valve
to this stage.'
For further details go to AorTech's website at: www.aortech.com
1 October 2001
ENQUIRIES:
Aortech International plc Tel: 01698 746 699
Eddie McDaid, Chief Executive
College Hill Tel: 020 7457 2020
Michael Padley
Nicholas Nelson
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.